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Introduction
Dengue (DEN) fever is the most diagnosed traveler-related 
illness, with 390–400 million cases/year worldwide1,2 and 
an incidence rate of ∼2.5%–5% of .2 billion people at risk.3 
However, only an estimated 3%–8% of symptomatic travelers 
are DEN virus (DENV)-positive via serological tests.4 Infec-
tion with one DENV serotype may cause a range of symptoms 
(eg, asymptomatic, flu-like). Simultaneous and/or sequential 
infection with different serotypes increases the risk of serious 
illnesses such as DEN hemorrhagic fever (DHF) and DEN 
shock syndrome, which could lead to death.5 Often, patients 
are unaware of initial infection and experience severe symptoms 
when secondary infection with another serotype occurs.5
A greater understanding of human travel patterns between 
DEN-endemic countries and the United States may improve risk 
assessments and identify potential routes of entry for DENV. 
The geographic ranges of the four DENV serotypes are expected 
to expand with international travel as humans are the primary 
reservoirs.6 This increases the likelihood of multi-serotype epi-
demics that could impact public health. Risk assessments show-
ing the impact of travel on DENV importation are essential to 
understand the role of human travel in pathogen spread.
Pan America can be categorized into four regions, that 
is, North America, Central America, South America, and 
 Caribbean. Most DEN cases among US citizens occur as a 
result of endemic transmission in Puerto Rico, a US territory.7 
In 2010, 162,058,000 visitors entered the United States.8 Of 
those, 1,197,866 were Brazilian.9 DEN is endemic in  Brazil 
where all four serotypes of DENV circulate.10 Travelers 
returning to the United States from Brazil accounted for 70% 
of imported DEN cases between 1998 and 2008.11,12
Globally, .2 billion people/year are at risk for DEN 
infection and .21,000 DEN-related deaths/year occur; yet, 
the range of possible symptoms makes it difficult for medical 
diagnoses without a serological test.13 Studies have identified 
young age, high body mass index, female sex, virus serotypes, 
and virus genotype as risk factors for severe DEN.13 Patients 
recovering from DHF may experience symptoms such as 
fatigue for up to six months.13
These increased risks are important due to the economic 
burden of lost work time and associated medical costs.14,15 
A study of 2012 healthcare costs in the Philippines reported 
$345 million ($3.26 per capita) spent in direct medical costs for 
patients with DEN.16 Pan American residents spend ∼$2.1 bil-
lion/year for DEN-related medical costs.17 In the United 
States, each person hospitalized with DEN pays ∼$17,803 
and less severe cases cost ∼$1,610.17 The median cost of medi-
cal treatment throughout Pan America is $1,227.17 Costs vary 
substantially between countries due to the value of currency 
and variation in expenses, that is, difference in costs between 
hospitals.18 Adequate healthcare facilities are not accessible to 
all patients with DEN, hence underreporting likely occurs.19
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DENV was first isolated in 1943, and serological tests 
were subsequently made available.19 Currently, DEN cases are 
diagnosed based on symptoms rather than serological tests 
that are used simply to confirm infection for research.19 Before 
1970, DEN had only been detected in nine countries; how-
ever, by 1996, 102 countries had experienced epidemics.20 In 
1962, a comprehensive mosquito control effort was developed 
and implemented by the Brazilian government, Pan American 
Health Organization (PAHO), and the Rockefeller Founda-
tion.19 Although this effort attempted to eradicate the pri-
mary DENV vector, Aedes aegypti L., reinfestation occurred 
when plans deteriorated due to the loss of political interest.12,19 
Insufficient community participation and lack of support from 
the health sector added to the deterioration of the eradication 
program.19 By 1980, DEN outbreaks increased globally, and 
in 1981, Cuba experienced an outbreak with 344,203 cases, 
including .10,000 DHF cases and .150 deaths.19 From 2000 
to 2012, all four DENV serotypes were found in Pan America, 
causing the highest number of cases to date.19
A. aegypti and Aedes albopictus Skuse are the two primary 
vectors of DENV and are distributed through Pan America.13 
A. albopictus, a day-biting species originally found in Asia, began 
geographic expansion in the 1980s and is still expanding today.21 
This anthropophilic mosquito species was introduced into the 
United States in 1985 from Asia in a shipment of tires.14,22–24 
A. aegypti takes multiple blood meals; hence, this species may 
infect multiple humans during a single gonotrophic cycle.25 This 
mosquito species will stop blood feeding when disturbed and 
either return to the same host or a different host to complete a 
blood meal.14,15 Rapid expansion of international and domestic 
human travel, urban sprawl, and insufficient vector control may 
facilitate the geographic expansion of DENV.19
Here, we conduct a risk assessment for 2001–2012 based 
on (1) residents and DEN cases in 51 Pan American countries, 
(2) visitors from 51 Pan American countries traveling to the 
United States, and (3) US residents traveling to DEN-endemic 
Pan American countries.
Materials and Methods
Travel statistics for 51 Pan American countries were tabulated 
from the Compendium of Tourism Statistics and the Office 
of Travel and Tourism Industries for 2001–2012 (Table 1).9 
Countries were categorized by region (ie, North America, 
Central America, South America, and Caribbean), and popu-
lations for 51 countries were tabulated.26 For the purposes of 
this study, North America includes Canada and the United 
States, while Mexico is included in Central America. The 
number of clinically reported DEN cases was collected from 
the PAHO10 and the Centers for Disease Control and Pre-
vention (CDC) (J. Lehman, personal communication). The 
number of DEN cases was compared to the annual travel sta-
tistics and populations for each region. Regions with the most 
visitors to the United States were ranked, and further analyses 
were conducted for 18 countries whose residents visited the 
United States most frequently. The incidence rate per 100,000 
people was determined ([the number of DEN cases reported 
in the country/the population of the country] × 100,000). Due 
to unreported data, Canada was excluded from North Amer-
ica for the purposes of calculating incidence rate. To deter-
mine the potential risk of traveling to an endemic country 
and becoming infected, the number of United States citizens 
traveling to each region was multiplied by the incidence rate 
for that region. This method was repeated for each consecutive 
year studied. The CDC provided information on DEN cases 
imported into the United States by citizen travelers from 2003 
to 2011 (J. Lehman, personal communication). The number of 
imported DEN cases from each of the same 18 Pan American 
countries (residents visited the United States most frequently) 
was divided by the total number of cases for each year in each 
country to determine the country where the highest rate of 
incidence occurred in United States travelers.
Maps were created using Environmental Systems Research 
Institute ArcMap 10.1 (ESRI). Incidence rates10 were input 
into attribute tables for specific countries. Graduated colors 
were used to display incidence rate per 100,000 people for each 
country. Maps were created for 2004, 2008, and 2012 to show 
spatiotemporal trends for the countries relevant to our study.
results
We generally observed yearly increases in international travel to 
the United States from all regions of Pan America from 2001 
to 2012 (Fig. 1). For the time period studied, most Pan Ameri-
can DEN cases occurred in Brazil (South American region), 
with .1 million cases reported in 2010 alone (Table 1). For 
US citizens, the highest number of imported DEN cases were 
observed in continental US travelers visiting the Dominican 
Republic, closely followed by Puerto Rico (Caribbean Region).
Table 1 shows that reported clinical cases of DEN have 
increased where surveillance systems have become a prior-
ity, such as Brazil (mandatory reporting started in 2007). The 
South American Region had the highest number of DEN cases 
over the 12 years studied (Fig. 2). Incidence rates in all regions 
have increased since 2001 with the worst epidemics occur-
ring in 2010 (Fig. 3). Of the 18 countries studied, Brazil (third 
highest number of travelers to United States) showed the high-
est number of DEN cases. The DEN incidence rate was high-
est in the South American region (341 cases/100,000 people in 
2010), primarily attributed to Brazil. The Caribbean and South 
American regions both experienced DEN epidemics in 2010, 
while Central America had an epidemic in 2009 (Fig. 2). How-
ever, there is a large population  difference between the South 
American Region and other regions such as the Caribbean, 
and Figure 3 accounts for these differences, that is, regional 
incidence with the population taken into account.
Figures 4–6 show DEN incidence in 2004, 2008, and 
2012, respectively. In 2004, several countries had incomplete 
data available due, in part, to underreporting. Countries with 
higher incidence rates have at least three DENV serotypes 
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Table 1. Serologically confirmed DEN cases in 51 Pan American countries from 2001 to 2012.
CoUnTRY YEAR
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
north America
Canada – – – – – – – – – – – –
United states 96 29 40 10 98 143 488 199 178 648 283 545
Central America
Belize 3 41 – 2 380 9 40 23 1,457 2,178 469 1,948
Costa rica 9,237 12,251 19,669 9,408 37,798 12,124 26,440 7,160 6,946 31,773 13,854 22,243
El salvador 1,093 18,307 7,436 13,344 15,290 22,088 12,476 5,774 15,040 22,406 20,836 41,793
guatemala 4,516 7,599 6,750 6,352 6,341 2,428 5,886 3,230 10,438 17,045 2,565 9,547
Honduras 9,077 32,269 16,559 19,971 18,843 8,436 33,508 18,941 15,291 66,814 8,297 15,554
mexico 6,210 9,844 5,018 8,202 16,862 27,287 48,436 31,154 249,763 57,971 67,918 164,947
nicaragua 2,104 2,157 2,799 1,035 1,735 1,350 1,415 1,424 17,140 6,261 11,888 30,499
Panama 1,545 711 293 373 4,000 4,300 3,402 2,287 6,811 1,243 3,882 1,329
South America
argentina 11 214 135 3,284 34 181 173 40 26,612 1,185 213 2,043
Bolivia 176 892 6,548 7,390 4,443 2,040 7,332 3,181 84,047 5,191 26,681 42,704
Brazil 416,067 780,644 341,902 112,928 203,789 346,550 559,954 734,384 528,883 1,004,392 764,032 565,510
Chile (only 
 Easter island)
– 636 – – – 3 28 25 27 – 1 34
Colombia 55,437 76,996 52,588 27,523 30,475 36,471 43,227 26,732 51,543 157,152 33,207 49,361
French guiana 2,830 280 2,178 3,147 4,365 15,930 661 460 11,330 4,350 667 1,372
guyana 60 202 33 47 178 118 201 324 994 1,468 1,093 2,189
Ecuador 10,919 5,833 10,319 6,165 12,131 6,044 10,587 1,894 4,489 1,042 7,659 18,995
Paraguay 38 1,871 137 164 405 4,271 28,182 1,953 6,143 13,553 42,945 33,063
Peru 23,329 8,875 3,637 9,774 6,358 5,531 6,907 10,278 8,813 18,392 29,810 29,994
suriname 760 1,104 285 375 2,853 285 41 24 120 113 409 781
Uruguay – – – – – – – – – – – –
venezuela 83,180 37,676 26,996 30,693 42,198 39,860 80,646 48,048 65,869 123,967 31,551 49,044
Caribbean
Cuba 11,432 3,011 – – 75 – 28 – 70 – – –
Dominican 
republic
3,592 3,194 6,163 2,476 2,860 6,143 9,628 4,333 8,292 11,519 2,339 9,665
Puerto rico 5,233 2,906 3,735 3,288 5,701 3,043 11,012 3,384 6,651 21,298 5,654 12,877
american  
virgin islands
– – – – – – 73 – – – – –
anguilla 25 5 2 – – – – 9 – 1 9 9
antigua and 
Barbuda
20 5 – – – – – 17 – 3 7 10
aruba – 25 – 173 – 5 – – 845 1,415 3,027 667
Bahamas – – 180 1 – – – 1 – 8 7,000 5
Barbados 1,043 740 557 349 320 1 – 1 55 2,917 745 1,445
Bermuda – – – – 2 2 – – – 2 1 –
British virgin 
islands
23 – – – 1 – 6 15 65 9 939 214
Cayman  
islands
– 1 1 – 1 – 9 1 – 8 2 53
Curacao – – – – 265 – – – – 1,723 1,555 721
Dominica 5 – – 4 11 19 111 80 2 635 40 29
grenada 12 84 17 7 – 22 – 6 23 125 87 75
(Continued )
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figure 1. international travel to the United states from Pan american 
regions.
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figure 2. Serologically confirmed DEN cases in Pan American regions.  
note: Data from Canada are not included since DEn is not a reportable 
infection.
Table 1. (Continued )
CoUnTRY YEAR
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
guadeloupe – 93 495 – 3,364 2,948 3,266 2,234 2,234 41,100 824 1,032
Haiti – – – – – – – – – – – 240
Jamaica 39 90 52 9 46 79 1,448 359 70 2,827 408 4,670
martinique 4,471 392 791 – 6,083 4,086 5,082 586 1,378 37,100 275 1,269
montserrat 1 1 1 – – – – 2 – – 3 1
netherlands 
antilles
– – – – – – – – – 852 939 121
st. Bartolome – – – – – – – – 805 – 23 32
st. Kitts and 
nevis
89 20 2 4 – 1 – 49 2 19 47 1
st. lucia 292 51 5 11 1 – 39 98 18 74 585 33
st. martin – – – – – – – – 1,698 2,450 168 253
st. vincent 
and the 
grenadines
3 125 3 4 8 5 2 6 10 133 47 193
trinidad and 
tobago
2,244 6,246 2,289 546 411 37 47 2,366 24 2,497 1,243 2,473
turks and 
Caicos islands
– – 2 1 1 – – – – – 24 16
note: –, data not available.9,10
circulating (eg, Brazil, Venezuela, and Mexico), and its residents 
travel to the United States most frequently. Table 2 shows that 
the number of DENV serotypes in most countries increased 
between 2004 and 2012. Caution is advised in interpreting 
Figures 1 and 2 since most countries did not mandate DEN 
reporting until 2009.
discussion
Most US citizens experiencing DEN acquired the illness 
while visiting the Dominican Republic, closely followed 
by Puerto Rico (Caribbean Region). Countries endemic 
for DEN pose a higher risk for travelers than nonendemic 
countries and thus create a higher risk for DENV incidence 
and spread. As travel and geographic range of potential 
DENV vectors continue to increase, incidence of DEN will 
likely increase.14 There is also an increased risk of introduc-
ing new DENV serotypes into naïve populations. Regions 
that are visited frequently and where all four DENV sero-
types are prevalent (eg, South America) pose the greatest 
risk to travelers.
A. albopictus and A. aegypti are both found in the United 
States; hence, traveler-imported cases are a concern for some 
Trends in dengue cases imported into the United States
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figure 3. incidence rate of DEn infection in Pan american regions. 
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not included since DEn is not a reportable infection.
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figure 4. DEn incidence rates in Pan america in 2004.
regions since local mosquito populations may contribute to 
subsequent transmission. Florida had 125 locally trans-
mitted cases from 2009 to 2014, while Hawaii (four cases 
in 2011), Texas (24 cases from 2013), and New York (one 
case in 2013) also experienced locally transmitted cases.15,27 
In the United States, there were 177 imported human 
DEN cases reported from 22 different states in 2009, 642 
imported cases from 39 states in 2010, 245 imported cases 
from 32 states in 2011, 544 imported cases from 34 states in 
2012, 772 imported cases from 41 states in 2013, and 357 
imported cases from 37 different states in 2014 (J. Lehman, 
personal communication27).
Until 2009, DEN was not a nationally reportable dis-
ease in many Pan American countries, including the United 
States; hence, cases prior to 2009 may be underreported. 
Some countries only report serologically positive cases; hence, 
physician-diagnosed cases (relying solely on symptoms) may 
be underreported.10 Increases in DEN cases reported here 
after 2009 may be an indication of improved surveillance in 
addition to increasing incidence of cases.
While underreporting and misdiagnosis remain an 
issue for calculating DENV transmission risk, we observed 
increases in case frequency for the period studied. Many 
patients infected with one serotype of DENV are asymptom-
atic or experience flu-like symptoms and do not seek medical 
treatment.28 Others cannot afford to go to the doctor or do not 
have easy access for treatment and, therefore, go unreported.14 
There is a lack of uniform application of the case definition 
of DEN, and some countries have instituted their own case 
definitions.29 In addition, complicated reporting systems and/
or lengthy reporting requirements may reduce motivation of 
health care workers to submit positive test results.3 Under-
reporting impacts public health because it is an enormous 
Dodewaard and Richards
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barrier to obtaining an accurate risk assessment. In Belo 
Horizonte, Brazil, the level of reporting of hospitalized 
patients with DEN was ∼63% between 1997 and 2002.30
Identification of DENV via cell culture or nucleic acid 
detection (polymerase chain reaction) requires sophisticated 
laboratories,31 and there is limited accuracy in rapid tests.3 As 
a result, the mobilization of resources from the local, national, 
and international communities for the elimination of the vec-
tor and better infection care3 needs improvement.
There is no DEN vaccine,32 and there is great concern for 
people already infected with one or more serotypes regarding 
their reaction to a vaccine.33 With .43 million travelers entering 
the United States by air from Pan American countries, the risk 
for travel-related DEN exists. Continued surveillance, improved 
DEN-reporting systems, and risk assessment are needed to pre-
vent further DEN expansion and reduce the risk of importation.
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